Mode
Text Size
Log in / Sign up
Phase 2 N=25 Treatment

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Enrolled (actual)
25
Serious AEs
91.8%
Results posted
Jul 2015
Primary outcome: Primary: Overall Objective Response Rate During Treatment Cycle 1 — 57.1; 100.0; 30.8 percentage of participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Blinatumomab (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Amgen Research (Munich) GmbH
Primary completion
Jul 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Overall Objective Response Rate During Treatment Cycle 1
57.1; 100.0; 30.8
SECONDARY
Percentage of Participants With a Best Overall Response of Complete Response
28.6; 0; 15.4
SECONDARY
Percentage of Participants With a Best Overall Response of Partial Response
28.6; 100.0; 15.4
SECONDARY
Duration of Objective Response
8.7; NA; 4.0
SECONDARY
Duration of Complete Response
NA; NA
SECONDARY
Duration of Partial Response
3.3; NA; 2.0
SECONDARY
Progression-free Survival (PFS)
3.7; NA; 1.6
SECONDARY
Overall Survival (OS)
20.1; NA; 3.6
SECONDARY
Number of Participants With Adverse Events
9; 2; 14; 9; 2; 13
SECONDARY
Blinatumomab Steady State Serum Concentration
277; 565; 2800
SECONDARY
Leukocyte Counts
6.376; 5.729; 6.819; 6.400; 3.764; 4.950
SECONDARY
Lymphocyte Counts
0.779; 0.491; 0.382; 0.277; 0.472; 0.847
SECONDARY
Monocyte Counts
0.638; 0.300; 0.202; 0.188; 0.318; 0.646
SECONDARY
Granulocyte Count
4.968; 4.910; 6.235; 5.935; 2.974; 3.457
SECONDARY
CD19+ B-Cell Count
0.026; 0.029; 0.001; 0.000; 0.000; 0.000
SECONDARY
CD19+ B-Cells as a Percentage of All Lymphocytes
2; 4; 0; 0; 0; 0
SECONDARY
CD3+ T-Cell Count
0.578; 0.349; 0.282; 0.199; 0.348; 0.613
SECONDARY
CD3+ T-Cells as a Percentage of All Lymphocytes
72; 68; 70; 67; 73; 71
SECONDARY
CD4+ T-Cell Count
0.254; 0.152; 0.131; 0.085; 0.170; 0.261
SECONDARY
CD4+ T-Cells as a Percentage of All Lymphocytes
33; 28; 32; 29; 34; 30
SECONDARY
CD8+ T-Cell Count
0.298; 0.186; 0.134; 0.102; 0.140; 0.299
SECONDARY
CD8+ T-Cells as a Percentage of All Lymphocytes
37; 37; 35; 35; 33; 37
SECONDARY
CD19+ B-Cell to CD3+ T-Cell Ratio
0.04; 0.07; 0.00; 0.00; 0.00; 0.00
SECONDARY
CD4+ T-Cell to CD8+ T-Cell Ratio
1.32; 1.16; 1.20; 1.03; 1.43; 0.96
SECONDARY
CD4+ Naive T Cell Count
0.028; 0.013; 0.014; 0.012; 0.032; 0.036
SECONDARY
CD4+ Naive T Cells as a Percentage of All CD4+ T-Cells
8; 7; 7; 10; 9; 10
SECONDARY
CD4+ Central Memory T-Cell (TCM) Count
0.048; 0.029; 0.027; 0.014; 0.032; 0.032
SECONDARY
CD4+ TCM Cells as a Percentage of All CD4+ T-Cells
18; 20; 19; 14; 13; 13
SECONDARY
CD4+ Effector Memory T-Cell (TEM) Count
0.161; 0.099; 0.083; 0.051; 0.097; 0.169
SECONDARY
CD4+ TEM Cells as a Percentage of All CD4+ T-Cells
41; 39; 36; 46; 34; 39
SECONDARY
CD8+ Naive T-Cell Count
0.029; 0.024; 0.010; 0.006; 0.012; 0.019
SECONDARY
CD8+ Naive T-Cells as a Percentage of All CD8+ T-Cells
10; 12; 9; 8; 8; 6
SECONDARY
CD8+ TCM Cell Counts
0.020; 0.014; 0.010; 0.004; 0.007; 0.012
SECONDARY
CD8+ TCM Cells as a Percentage of All CD8+ T-Cells
7; 8; 10; 4; 7; 9
SECONDARY
CD8+ Effector Memory T-Cell (TEM) Count
0.127; 0.075; 0.065; 0.045; 0.067; 0.135
SECONDARY
CD8+ TEM Cells as a Percentage of All CD8+ T-Cells
42; 42; 46; 43; 51; 46
SECONDARY
CD8+ Terminally Differentiated Effector Memory T-cells (TEMRA) Count
0.123; 0.072; 0.051; 0.047; 0.058; 0.132
SECONDARY
CD8+ TEMRA Cells as a Percentage of All CD8+ T-Cells
41; 39; 36; 46; 34; 39

Summary

The purpose of this study is to confirm whether the bispecific T-cell engager blinatumomab is effective and safe in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Eligibility Criteria

Inclusion Criteria

  • Patients with Diffuse Large B-Cell Lymphoma (DLBCL) who are refractory to first or later treatment or have a first relapse or later relapse not eligible for autologous hematopoietic stem cell transplant (HSCT) or relapsed post- autologous-HSCT
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Age ≥ 18 years
  • Life expectancy of ≥ 12 weeks
  • Cerebrospinal fluid (CSF) free of infiltration by DLBCL

Exclusion Criteria

  • History or presence of clinically relevant central nervous system (CNS) pathology as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis
  • Current infiltration of CSF by DLBCL
  • History of autoimmune disease with potential CNS involvement or current autoimmune disease
  • Autologous HSCT within six weeks prior to start of blinatumomab treatment
  • Prior allogeneic HSCT
  • Cancer chemotherapy within two weeks prior to start of blinatumomab treatment
  • Radiotherapy within four weeks prior to start of blinatumomab treatment
  • Immunotherapy (e.g., rituximab) within four weeks prior to start of blinatumomab treatment
  • Any investigational anti-lymphoma product within four weeks prior to start of blinatumomab treatment
  • Treatment with any other investigational product after signature of informed consent
  • Known hypersensitivity to immunoglobulins or to any other component of the study drug formulation
  • Abnormal laboratory values indicative of inadequate renal or liver function
  • History of malignancy other than non-Hodgkin's lymphoma (NHL) within five years prior to start of blinatumomab treatment with the exception of basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix
  • Active uncontrolled infection, any other concurrent disease or medical condition that is deemed to interfere with the conduct of the study as judged by the investigator
  • Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus or hepatitis C virus
  • Pregnant or nursing women
  • Previous treatment with blinatumomab
  • Presence of human anti-murine antibodies (HAMA) at screening
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01741792). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search